NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
Phase 3
Active, not recruiting
- Conditions
- DS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple Myeloma
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 452
- Registration Number
- NCT00098475
- Locations
- 🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
🇺🇸The Medical Center of Aurora, Aurora, Colorado, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Recurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityMetastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the Hypopharynx
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT00098631
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00098423
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the EsophagusAdenocarcinoma of the StomachRecurrent Esophageal CancerRecurrent Gastric Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00098527
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Phase 2
Terminated
- Conditions
- Clear Cell Renal Cell CarcinomaPapillary Renal Cell CarcinomaRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00098618
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
Phase 2
Completed
- Conditions
- Central Nervous System MetastasesHER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage IV Breast CancerTumors Metastatic to Brain
- Interventions
- Other: laboratory biomarker analysisProcedure: quality-of-life assessmentOther: questionnaire administration
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00098605
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00098501
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Phase 1
Terminated
- Conditions
- B-cell Chronic Lymphocytic LeukemiaProlymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Biological: rituximab
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00098488
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Drug: BAY 43-9006 (Sorafenib)
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00098254
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Podocyte Retinoids
Phase 2
Completed
- Conditions
- Glomerulosclerosis, Focal SegmentalCollapsing Glomerulopathy
- Interventions
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2017-12-13
- Target Recruit Count
- 12
- Registration Number
- NCT00098020
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States